Bullish Momentum: Nutriband Inc. (NASDAQ: NTRB) Triggers 17 Bullish Signals On Approx 38% Early Move

*Sponsored by Nutriband Inc. News Just Hit—See Why Nutriband Inc. (NASDAQ: NTRB) Is Topping Our Watchlist Right Now! Nutriband Inc. (NASDAQ: NTRB) Comes Backed By Several  Potential Catalysts Including: With fewer than 5.1M shares in the float and trending above key moving averages, (NTRB) has shown the potential for major swings, including an approximate 202% move in just one week. Over 54% of shares are insider-held, and Noble Capital’s $13 target suggests over 90% potential upside from yesterday’s range. Patent allowance for (NTRB)’s Aversa™ technology strengthens its intellectual property as it moves toward a planned NDA submission in late 2025. A 51% year-over-year revenue increase and $8.4M in fresh capital reinforce (NTRB)’s fiscal foundation as it works toward launching Aversa™ Fent-a-nyl, projected for $80M–$200M in U.S. sales. Consider taking a look at (NTRB) today. February 13, 2025 Dear Reader, Please tell me you have Nutriband Inc. (NASDAQ: NTRB) on your screen right now. Nutriband Inc. (NASDAQ: NTRB) just triggered 17 Bullish Signals on TradingView’s technical analysis tool using the 5 minute time-frame, including the Momentum Indicator. (NTRB) reached $9.88 in the early session, moving approximately 38% from yesterday’s $7.12 close. With everything lining up, this one just shot to the top of our watchlist—here’s why you need to see it now. Nutriband Inc. (NASDAQ: NTRB) has solidified its collaboration with Kindeva Dr-ug Delivery by formalizing an exclusive development partnership for Aversa™ Fent-a-nyl.  This agreement cements their long-term commitment, with shared development costs in exchange for milestone payments.  Aversa™ Fent-a-nyl combines Nutriband Inc. (NASDAQ: NTRB)’s proprietary abuse-deterrent technology with Kindeva’s FDA-approved fent-a-nyl patch, aiming to be the first of its kind in abuse prevention.   With patents secured in 46 countries, this partnership could accelerate progress toward regulatory approval and commercialization. This little-known pharma company has already turned heads twice, making approximate moves of 32% in under 24 hours and approx. 126% in less than 48 hours.  With this latest development, it’s back on our radar in a big way. Now, it’s going for the hat trick—and if you don’t know what that means, let’s clear it up. A hat trick is when the same player scores three times in a row.  And if this profile pulls it off again, anyone still sitting on the sidelines might start kicking themselves. Let’s not waste time. See why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning. Let’s call it like it is—few biotech companies are pushing boundaries quite like Nutriband Inc. (NASDAQ: NTRB). While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change.  In fact, Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% in one week, from $3.90 on January 16th to $11.78 on January 23, 2025. Analyst Target Suggests Over 90% Upside Potential Recently trending above several key moving averages, Nutriband Inc. (NASDAQ: NTRB) is showing strong technical momentum.  With its 50-day at $5.39, 100-day at $5.66, and 200-day at $5.49, (NTRB) is currently trending above all long-term indicators tracked by Barchart—a bullish signal that could suggest further upside potential.  Additionally, its year-to-date moving average of $6.29 reinforces the notion that (NTRB) has been maintaining strength despite broader market fluctuations. Backing this momentum, insider ownership stands at over 54% as of (yesterday) 2/12/2025—an exceptionally strong vote of confidence from those who know the company best.  With more than half of all shares held by insiders, leadership is signaling long-term commitment and belief in future growth. This combination of technical strength and a market cap under $77M, could position (NTRB) as a high-growth candidate compared to larger players in the same space. Less than a month ago, Noble Capital’s Robert LeBoyer initiated coverage on (NTRB) with a Bullish Rating and a $13 target, which suggests over 90% upside potential from yesterday’s $6.90 open. Nutriband Inc. (NASDAQ: NTRB) Advances Phase 1 Trial,  Eyes FDA Filing in 2025 At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, which is expected to showcase the effectiveness of its abuse-deterrent technology, setting up for an NDA filing by late 2025 and potential FDA approval in 2026. With a clear roadmap and strong momentum, Nutriband Inc. (NASDAQ: NTRB) continues to gain attention.  While many companies struggled to stay relevant, (NTRB) stayed on course, reinforcing its strategy and delivering results. Nutriband Inc. (NASDAQ: NTRB) received a Notice of Allowance from the USPTO for its Aversa™ abuse-deterrent transdermal technology.  This expected patent issuance further strengthens its intellectual property portfolio and positions it as a key player in abuse-deterrent pharmaceuticals. Aversa™ Fent-a-nyl could be the first and only abuse-deterrent pain patch on the market, addressing a critical need in pain management.  Expanding Global Reach & Strengthening Market Position With patents secured in 46 countries—including the U.S., Europe, China, and Japan—Nutriband Inc. (NASDAQ: NTRB) is solidifying its global presence.  A recent U.S. trademark allowance further reinforces its leadership in transdermal abuse-deterrent technology.  If Aversa™ Fent-a-nyl reaches commercialization, U.S. sales projections range from $80M to $200M annually. Fiscal Strength & Growth Momentum Nutriband Inc. (NASDAQ: NTRB) continues to demonstrate strong financial performance, driven by its subsidiary Pocono Pharma: Q3 revenue up 51% year-over-year. $8.4M in fresh capital from a private placement strengthened fiscal reserves. This foundation supports the company’s efforts to bring Aversa™ Fent-a-nyl to market. Regulatory Progress & Market Expansion With an NDA submission planned for late 2025, Nutriband Inc. (NASDAQ: NTRB) is preparing for an expedited FDA review.  Meanwhile, strategic manufacturing partnerships and international licensing agreements are setting the stage for scalability beyond the U.S. market. A Pipeline with Potential—(NTRB) Targets Key Markets & Innovation Aversa™ Fent-a-nyl is just the beginning.  Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications, with Buprenorphine alone estimated to reach $130M annually. Nutriband Inc. (NASDAQ: NTRB) is expanding beyond pharmaceuticals with its consumer health and retail partnerships: Collaborations with Target, Walmart, Walgreens, and CVS. Exclusive supplier agreement with Fit For Life Group (Adidas, Reebok, New Balance). Launch of a Mosquito Repellent Patch in Costa Rica, tapping into the Central and South American markets. Strengthening the Brand with a Global Champion As Nutriband Inc. (NASDAQ: NTRB) continues to expand beyond pharmaceuticals, it has brought in elite athletic expertise to enhance its consumer product lineup. World and European Wrestling Gold Medalist and Olympic Silver Medalist Anastasia Nichita has joined Nutriband Inc. (NASDAQ: NTRB)’s Product Advisory Board, focusing on brand expansion and global promotion of its over-the-counter sports and consumer products. CEO Gareth Sheridan highlighted Nichita’s addition as a strategic move to amplify Nutriband’s market presence, leveraging her experience and international influence in the athletic world. Through its subsidiary Pocono Pharma, Nutriband produces various consumer products, including AI Tape—a kinesiology tape infused with soothing and therapeutic ingredients. With this high-profile appointment, Nutriband is reinforcing its commitment to innovation and brand expansion in the sports and wellness market. Why It Matters The opi-oid crisis remains one of the most pressing public health challenges. Nutriband Inc. (NASDAQ: NTRB) is not just talking about solutions—it’s delivering them. AVERSA™ technology is designed to prevent misuse, accidental exposure, and abuse of high-risk transdermal drugs. CEO Gareth Sheridan summed it up: Nutriband Inc. (NASDAQ: NTRB) is on the brink of a transformative period. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 5 Reasons Why Nutriband Inc. (NASDAQ: NTRB) Is Topping  Our Watchlist This Morning… 1. Low Float & Strong Technicals: With fewer than 5.1M shares in the float and trending above key moving averages—including the 50-day at $5.39, 100-day at $5.66, and 200-day at $5.49—(NTRB) has demonstrated the potential for major swings, including an approximate 202% move in just one week. 2. High Insider Confidence & Analyst Target: Over 54% of shares are insider-held, and Noble Capital’s Robert LeBoyer recently assigned a $13 target, suggesting over 90% potential upside from yesterday’s range. 3. Patent Strength & Regulatory Milestones: The USPTO has issued a Notice of Allowance for (NTRB)’s Aversa™ abuse-deterrent technology, further reinforcing its intellectual property and positioning it as a leader in abuse-deterrent pharmaceuticals, with a planned NDA submission in late 2025. 4. Fiscal Growth & Market Expansion: (NTRB) reported a 51% year-over-year revenue increase and secured $8.4M in fresh capital, reinforcing its fiscal foundation as it works toward launching Aversa™ Fent-a-nyl, a product with projected U.S. sales potential of $80M–$200M annually. 5. Global Reach & Retail Partnerships: With patents secured in 46 countries, including the U.S., Europe, China, and Japan, (NTRB) is expanding internationally while also growing its consumer health presence through partnerships with Target, Walmart, Walgreens, and CVS. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to Your  Radar This Morning… With momentum building and key developments falling into place, Nutriband Inc. (NASDAQ: NTRB) is one little-known company to keep an eye on. A low float, strong technical positioning, and a patent portfolio spanning 46 countries all point to a company making serious strides. Insider confidence remains strong, with over 54% of shares listed as being held by insiders and a bullish $13 analyst target highlighting the road ahead. At the same time, (NTRB) is broadening its market reach through major retail partnerships and preparing for a key regulatory milestone that could set Aversa™ Fent-a-nyl apart. With a 51% revenue boost and $8.4M in fresh capital backing its next steps, this one stays firmly on our radar. We're watching (NTRB) closely this morning. As of this writing, Nutriband Inc. (NASDAQ: NTRB) was triggering 17 Bullish Signals following an approximate 38% early move.  More updates coming soon—stay tuned. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: stocknewstrends.com/disclosure/  *Pursuant to an agreement between TD Media LLC and Nutriband Inc., TD Media LLC has been hired for a period beginning on 02/13/2025 and ending on 02/14/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, TD Media LLC has been paid seventy-five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). To date, including under the previously described agreement, TD Media LLC has been paid four hundred thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither TD Media LLC or its member owns shares of (NTRB:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/ntrb/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice